Table 1.
Demographic characteristics
| Parameters | Group 1 (REM 100 mg; n = 224) | Group 2 (REM 250 mg; n = 241) | Group 3 (DAP 10 mg; n = 146) |
|---|---|---|---|
| Age (years) | 50.86 ± 8.76 | 50.87 ± 8.49 | 50.15 ± 9.90 |
| Sex | |||
| Male | 128 (57.1) | 127 (52.7) | 85 (58.2) |
| Female | 96 (42.9) | 114 (47.3) | 61 (41.8) |
| BMI (kg/m2) | 28.19 ± 4.62 | 27.82 ± 4.77 | 28.00 ± 4.96 |
| Bodyweight (kg) | 71.24 ± 11.63 | 70.11 ± 12.44 | 72.10 ± 12.81 |
| Height (cm) | 159.2 ± 9.38 | 158.9 ± 8.78 | 160.6 ± 9.18 |
| HbA1c (%) | 8.19 ± 0.79 | 8.28 ± 0.82 | 8.26 ± 0.81 |
| SBP (mmHg) | 124.9 ± 7.93 | 124.5 ± 8.69 | 124.6 ± 7.68 |
| DBP (mmHg) | 80.3 ± 5.52 | 79.6 ± 5.59 | 78.9 ± 5.04 |
| eGFR (mL/min/1.73 m2) | |||
| Male | 87.9 ± 18.91 | 88.5 ± 20.20 | 89.1 ± 15.73 |
| Female | 88.5 ± 19.06 | 86.3 ± 19.56 | 87.3 ± 17.92 |
Data are presented as n (%) or mean ± standard deviation
BMI body mass index, DAP dapagliflozin, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, REM remogliflozin, SBP systolic blood pressure